IVIG does not prevent further losses among women with primary recurrent spontaneous pregnancy loss. A potential effect has been demonstrated in the less prevalent problem of secondary recurrent spontaneous pregnancy loss. The published data are insufficient, however, to exclude the possibility that the treatment also has no value in the latter condition. Severe side effects of IVIG are rare in well-selected patients. The potential for harm from immunotherapy during pregnancy cannot be excluded, and potential risk of using a preparation derived from pooled plasma cannot be assessed from currently available data.
IVIG treatment is expensive.
Conclusion IVIG as a treatment for recurrent pregnancy loss should be evaluated in patients who are informed, consenting participants in an institutional review board approved randomized clinical trial. For the management of recurrent spontaneous pregnancy loss IVIG is an experimental treatment. The Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide Collaborative Observational Study and Meta-Analysis on Allogenic Leukocyte Immunotherapy for Recurrent Spontaneous Abortion. Coulam CB, Krysa LW, Bustillo M. Intravenous immunoglobulin for in vitro fertilization failure.